London, UK / New York, USA – A monumental collaborative study, spearheaded by researchers from the Francis Crick Institute, UCL, Gustave Roussy, and Memorial Sloan Kettering Cancer Center (MSK), has unveiled a critical link between the natural ageing process and cancer progression. Published today in the prestigious New England Journal of Medicine, the findings demonstrate that an expansion of mutant blood cells, a common phenomenon in older individuals, can infiltrate cancerous tumours, a condition termed tumour-infiltrating clonal haematopoiesis (TI-CH), and is directly associated with significantly worse prognoses for patients across a spectrum of cancer types.
This unprecedented research illuminates a previously underappreciated interface between age-related genetic changes and the evolution of solid cancers. The discovery marks a significant leap forward in understanding how the body’s intrinsic ageing mechanisms can inadvertently fuel aggressive disease, offering new avenues for diagnosis, prognostication, and potentially, novel therapeutic interventions. With a growing global elderly population, deciphering these intricate biological connections is paramount to developing more effective preventative and treatment strategies for age-related diseases, including cancer and cardiovascular conditions.
The Unseen Hand of Ageing: Clonal Haematopoiesis and Cancer
The human body is a complex ecosystem, constantly renewing its cells. As we age, however, this process can become imperfect. One such age-related phenomenon is clonal haematopoiesis of indeterminate potential (CHIP). CHIP occurs when blood stem cells, responsible for generating all blood components, accumulate specific genetic mutations over time. Influenced by both the natural ageing process and external environmental factors, these mutations lead to the expansion of a "clone" of mutated blood cells. While often asymptomatic, CHIP has long been recognized for its association with an increased risk of various age-related disorders, notably cardiovascular disease. However, its direct impact on the evolution and aggression of solid cancerous tumours remained a largely unexplored frontier – until now.
The collaborative research team embarked on an ambitious journey to bridge this knowledge gap. Their investigation, a meticulous and large-scale endeavour, initially focused on over 400 patients with lung cancer, a particularly aggressive and challenging malignancy. This cohort was drawn from the Cancer Research UK-funded TRACERx and PEACE studies, world-leading programmes dedicated to understanding cancer evolution and metastasis. To validate and broaden their findings, the team then expanded their analysis to an astonishing 49,000 patients with a diverse array of cancer types, leveraging the extensive clinical and genomic databases at Memorial Sloan Kettering Cancer Center in the United States. This multi-institutional, multi-cohort approach provided an unparalleled statistical power and clinical relevance to their groundbreaking observations.
A Chronology of Discovery: Tracing the Link from Blood to Tumour
The research unfolded in a series of meticulously planned stages, each building upon the previous, gradually revealing the insidious connection between CHIP and cancer outcomes.
Initial Observations: CHIP and Prognosis
The first phase of the study involved a comprehensive examination of blood samples collected from the initial cohort of lung cancer patients. Researchers painstakingly screened these samples to identify the presence of CHIP mutations in their blood cells. What they uncovered was stark: patients carrying these CHIP mutations in their blood exhibited a significantly shorter overall survival period compared to those without CHIP. Crucially, this association held true regardless of other influential factors such as the patient’s age at diagnosis or the stage at which their cancer was identified, pointing to CHIP as an independent prognostic indicator. This initial finding was a powerful signal, suggesting that age-related blood changes were not merely a bystander but an active participant in the cancer journey.
The Emergence of Tumour-Infiltrating Clonal Haematopoiesis (TI-CH)
While the presence of CHIP in the blood was clearly linked to worse outcomes, the researchers hypothesized that a more direct interaction might be at play. They questioned whether these mutant blood cells could actually infiltrate the cancerous mass itself. To investigate this, they delved deeper, analyzing the genetic makeup of the lung tumours from patients already identified with CHIP. Their suspicions were confirmed: in a striking 42% of patients with CHIP, the very same age-related mutations found in their blood were also detected within their lung tumours. This pivotal discovery led to the coining of a new term: tumour-infiltrating clonal haematopoiesis (TI-CH).
The distinction between CHIP (mutations in blood) and TI-CH (mutations within the tumour) proved to be profoundly significant. Further analysis revealed that it was TI-CH, not merely the presence of CHIP in the blood, that was primarily associated with the heightened risk of cancer relapse and, ultimately, cancer-related death. This finding shifted the focus from a systemic blood condition to a localized, active participant within the tumour microenvironment.
Validation Through Post-Mortem Analysis
The robustness of the TI-CH discovery was further cemented by data from the PEACE study, a unique post-mortem investigation designed to understand the landscape of metastatic disease – the primary cause of cancer death. By analyzing samples from various sites where cancer had spread, the team found compelling evidence that these metastatic tumours frequently harboured TI-CH mutations. This observation provided critical independent validation, underscoring the pervasive and detrimental role of TI-CH in advanced and fatal cancer progression. The chronological progression of the research, from initial blood screening to in-depth tumour analysis and post-mortem confirmation, paints a compelling picture of a previously hidden mechanism driving cancer aggression.
Supporting Data: Unpacking the Mechanism and Broadening the Scope
The initial correlation established, the researchers then meticulously delved into the underlying biological mechanisms, seeking to understand how TI-CH exerts its detrimental influence on tumour progression. This phase of the study involved detailed cellular and genetic analysis, culminating in experimental validation and broad-scale clinical confirmation.
Not All Immune Cells Are Equal: The Role of Myeloid Cells
To inspect the link between TI-CH and poor patient outcomes, the scientists meticulously examined the cellular composition within the lung tumours. They discovered a consistent pattern: patients with TI-CH exhibited a significant expansion of myeloid cells, a specific type of immune cell, within their tumours. This finding was crucial because the tumour microenvironment (TME) – the complex ecosystem surrounding a tumour – is known to be heavily influenced by immune cells. Unlike some immune cells, such as T-cells, which are "primed" to recognize and actively fight cancer, myeloid cells have a more nuanced and sometimes contradictory role. While essential for wound healing and inflammation regulation, certain subsets of myeloid cells, particularly when dysregulated, have been shown to actively suppress anti-tumour immune responses and instead support tumour progression, angiogenesis (new blood vessel formation), and metastatic spread. The expansion of these pro-tumourigenic myeloid cells within the TME, therefore, presented a plausible mechanism for TI-CH’s negative impact.
The Crucial Role of the TET2 Gene
Further investigation focused on specific genetic mutations implicated in CHIP and TI-CH. Among thousands of individuals studied, mutations affecting a gene called TET2 emerged as particularly significant. TET2 is a vital regulator of blood cell production, playing a key role in epigenetic modifications that control gene expression. The researchers discovered that blood cells carrying TET2 mutations were significantly more likely to infiltrate tumours. To confirm the cellular origin of these mutations within the TME, the team performed high-resolution single-cell analysis on hundreds of individual cells isolated from the tumours of two patients with TI-CH. This intricate analysis definitively confirmed that TET2 mutations were predominantly present in myeloid cells, and not in other immune cell types, solidifying the link between TET2 mutation, myeloid cell expansion, and tumour infiltration.
Experimental Validation: Organoids and Accelerated Growth
To move beyond correlation and establish a causal link, the research team collaborated with experts in blood cancer and CHIP at the Crick, led by Dominique Bonnet. Together, they designed elegant experimental models. They grew "organoids" – mini lung tumours – in vitro, and then co-cultured these organoids with TET2 mutant myeloid cells. The results were compelling: the TET2 mutant myeloid cells actively remodelled the tumour microenvironment, creating conditions more favourable for cancer growth, and strikingly, accelerated the growth of the tumour organoids. This direct experimental evidence provided a robust functional validation, demonstrating that TET2 mutant myeloid cells are not merely bystanders but active contributors to tumour progression.
Broad Validation Across 49,000 Cancer Patients
Recognizing the importance of generalizability, the team then undertook a massive validation effort in collaboration with researchers at Memorial Sloan Kettering Cancer Center. They analyzed a colossal dataset comprising over 49,000 patients spanning a wide range of different cancer types. The findings from this extensive analysis resonated with and amplified their initial observations: the presence of TI-CH was confirmed as an independent predictor of shorter survival across this incredibly diverse cohort.
While TI-CH was a consistent negative prognostic factor, the study also revealed interesting variations in the prevalence of CHIP and TI-CH across different cancer types. These mutations were found to be significantly more common in cancers known for their aggressive nature and inherent resistance to treatment, such as lung cancer (the initial focus), head and neck cancer, and pancreatic cancer. This correlation suggests that TI-CH might be a particularly potent driver in these notoriously difficult-to-treat malignancies, potentially explaining some of their inherent aggressiveness and poor outcomes. The sheer scale and multi-cancer validation of this part of the study elevate the findings from a specific observation to a broad, clinically significant phenomenon with profound implications for oncology.
Official Responses: Experts Weigh In on a Paradigm Shift
The publication of these findings has been met with significant enthusiasm within the scientific and medical communities, underscoring the profound implications for our understanding of cancer and ageing.
Dr. Oriol Pich, a Postdoctoral Project Research Scientist in the Crick’s Cancer Evolution and Genome Instability Laboratory and one of the lead authors, emphasized the direct impact of the discovery: "Our results show that blood cells carrying age-related mutations can infiltrate tumours and impact cancer evolution, leading to worse outcomes for patients. This is important because CHIP is a natural phenomenon of ageing that is common in patients with cancer." Dr. Pich’s statement highlights the ubiquity of CHIP in the cancer patient population, suggesting that this newly discovered mechanism could be influencing a vast number of cancer cases globally. It also underscores the critical need to consider the broader systemic environment of the patient, beyond just the tumour itself, when assessing prognosis and planning treatment.
Professor Charlie Swanton, Deputy Clinical Director at the Crick, Chief Clinician at Cancer Research UK, and Chief Investigator for TRACERx, spoke to the groundbreaking nature of the interaction observed: "This is the first time that we’ve been able to see at scale, the interaction of two different types of ‘clonal proliferations’, age-related CHIP and cancer, providing insight into how ageing might impact cancer risk." Professor Swanton’s remarks point to a paradigm shift, recognizing that cancer evolution is not solely an internal tumour process but can be significantly influenced by concurrent, age-related clonal expansions elsewhere in the body. He articulated a hopeful vision for the future: "As we start to piece together the picture of the most important mutations which evolve during the ageing process in cells from the bone marrow, and the impact they have in disease, we hope we can start to identify opportunities for intervention and maybe even prevention of some age-related cancers." His forward-looking perspective underscores the potential for this research to pave the way for entirely new strategies, not just for treating advanced cancers, but potentially for preventing them in at-risk individuals.
The scientific community recognizes this work as a testament to the power of interdisciplinary collaboration, bringing together expertise in cancer evolution, haematopoiesis, immunology, and large-scale data analysis. This synergy was crucial in unraveling such a complex biological interplay.
Implications: Charting the Course for Future Cancer Care
The profound implications of this study extend across the entire spectrum of cancer care, from risk assessment and prognosis to the development of novel therapies and even preventative strategies.
Enhanced Prognostication and Biomarkers:
The most immediate impact of this discovery lies in its potential to refine cancer prognosis. The presence of TI-CH could serve as a powerful new biomarker, enabling clinicians to identify patients at higher risk of relapse and death, independent of traditional factors like tumour stage or patient age. This early identification could lead to more personalized and aggressive treatment strategies for those patients most likely to benefit, potentially including closer monitoring or adjuvant therapies. Routine screening for CHIP, and subsequently for TI-CH in tumour biopsies, could become a standard component of cancer diagnostic workups.
Novel Therapeutic Avenues:
The mechanistic insights gained from this research open up entirely new avenues for therapeutic development. If TET2 mutant myeloid cells actively remodel the tumour microenvironment to accelerate growth, then targeting these specific cells or their pro-tumourigenic pathways could represent a groundbreaking therapeutic strategy. This might involve developing drugs that inhibit the inflammatory signals produced by these myeloid cells, or even therapies that selectively deplete TET2 mutant cells within the tumour. Such an approach would represent a significant departure from traditional cancer treatments that primarily target the cancer cells themselves, instead focusing on the broader, supportive environment that fuels their growth. This "microenvironment-centric" approach could prove particularly effective in those hard-to-treat cancers where TI-CH is more prevalent.
Towards Prevention and Early Intervention:
Perhaps the most exciting long-term implication lies in the realm of cancer prevention. As Professor Swanton alluded, understanding how age-related mutations impact cancer risk could lead to interventions designed to mitigate the effects of CHIP before cancer even develops. Could lifestyle modifications, anti-inflammatory drugs, or other early interventions reduce the prevalence or impact of CHIP, thereby lowering the risk of aggressive cancer formation? Further research is crucial to confirm that CHIP directly contributes to cancer outcomes and to detail the exact mechanisms by which CHIP is functionally implicated in the development of aggressive cancers. Answering these questions could unlock strategies for managing CHIP as a pre-cancerous condition, much like how certain precancerous lesions are currently monitored and treated.
A Deeper Understanding of Ageing and Disease:
Finally, this work contributes significantly to our overarching understanding of the biological interface of age-related genetic changes and diseases of ageing. It reinforces the idea that ageing is not merely a passive decline but an active process with specific molecular and cellular changes that can profoundly influence the onset and progression of major diseases like cancer. This holistic view will be essential as societies grapple with the increasing burden of age-related illnesses.
This pivotal research, supported by Cancer Research UK, the National Institute of Health and Care Research UCLH Biomedical Research Centre, and additional funders, marks a new chapter in oncology. By shining a light on the insidious interaction between ageing blood cells and cancerous tumours, it offers a powerful new lens through which to view cancer, promising a future of more precise diagnoses, innovative treatments, and ultimately, a better outlook for patients facing this formidable disease. The journey to fully harness these insights has just begun, but the path forward is now clearer than ever.
About the Author
